Resources

There is a gender gap in some responses to the new intranasal insulin still in research.

Diabetic retinopathy appears to be an independent risk factor for heart failure, new research suggests, which supports the belief that microvascular disease plays a role in the development of heart failure in diabetics.

Metabasis Therapeutics unveiled another diabetes treatment. This one cuts down on glucose production by the liver. It works by inhibiting an enzyme called Fructose-1,6-bisphosphatase. Metformin, a standard drug for diabetes patients, also cuts down on glucose production in the liver, but how it works is a mystery.

A new type of bariatric surgery may eliminate the need for medication in patients with type 2 diabetes, according to a study reported here at the Society of American Gastrointestinal and Endoscopic Surgeons 2008 Annual Scientific Session and Postgraduate Course.

Jenny Ruhl (2008) Reviewed by Karen Linz, JD, MBA, PharmD Candidate, University of Florida College of Pharmacy Blood Sugar 101 is written specifically for Type 2 diabetics to let them know that it is possible for people with diabetes to achieve normal blood glucose levels, and that by doing so, …

The debate about ‘how low to go’ is not new and traditionally has been waged between the ‘true believers,’ those with a strong a priori conviction that more aggressive pharmacological treatment will reduce future events, and the ‘therapeutic nihilists,’ those who require unequivocal proof before acceptance. In recent years, the …

A genetic study of diabetes by scientists from Imperial College has been named as one of the hottest research papers of 2007. We may soon be able to predict who will get Type 2 diabetes.:

A study was done to compare the prevalence of classical cardiovascular risk factors (CVRF) and metabolic syndrome (MetS) in our population according to fasting plasma glucose levels (FPG).

Researchers speculate that insulin problems could damage blood vessels in the brain. Men who develop diabetes in middle age may be at greater risk of Alzheimer’s disease, a Swedish study finds.

Phase III study will evaluate effects of otelixizumab, an investigational anti-CD3 monoclonal antibody, on preservation of endogenous insulin secretion